We report a 46-year-old male who developed cellulitis of his third right finger after being injured with a metallic object. Cryptococcus neoformans var. neoformans was isolated from both the skin and the metallic object. Systemic cryptococcosis and immunosuppression was excluded by appropriate tests. Complete healing was achieved after 10 months of itraconazole 100 mg/12 h and surgical excision of the remaining lesion. Our literature review shows another 16 cases of primary cutaneous cryptococcosis in nonimmunocompromised hosts. The clinical, mycological and therapeutic characteristics of these patients are reviewed.

Keywords:
Cryptococcus neoformans, Cellulitis, Immunocompetence, Itraconazole
1.
Hay RJ: Cryptococcus neoformans and cutaneous cryptococcosis. Semin Dermatol 1985;4:252–259.
2.
Hernández AD: Cutaneous cryptococcosis. Dermatol Clin 1989;7:269–274.
3.
Diamond RD: Cryptococcus neoformans; in Mandel GL, Bennett JE, Dolin R (eds): Mandell, Douglas and Bennett’s Principles and Practice of Infectious Diseases. New York, Churchill Livingstone, 1995, pp 2331–2340.
4.
Pal M, Mehrotra BS: Studies on the isolation of Cryptococcus neoformans from fruits and vegetables. Mykosen 1985;28:200–205.
5.
Rook A, Woods B: Cutaneous cryptococcosis. Br J Dermatol 1962;74:43–49.
6.
Miura T, Akiba H, Saito N, Seiji M: Primary cutaneous cryptococcosis. Dermatologica 1971;142:374–379.
7.
Blanc C, Bazex J: Un cas de cryptococcose cutanée primitive chez un sujet sain. Ann Dermatol Vénéréol 1979;106:807–811.
8.
Bee OB, Tan T, Pang R: A case of primary cutaneous cryptococcosis successfully treated with miconazole. Arch Dermatol 1981;117:290–291.
9.
Webling D, Mahajani A: Localized dermal cryptococcosis following a scorpion sting. Aust J Dermatol 1981;22:127–128.
10.
Glaser JB, Garden A: Inoculation of cryptococcosis without transmission of the acquired immunodeficiency syndrome. N Engl J Med 1985;313:266.
11.
Salm R, Groth D, Kappe R, Müller J: Primary cutaneous cryptococcosis after microtrauma of the right index finger. Mycoses 1988;21(suppl 1):88–92.
12.
Sato T, Kpseki S, Takahashi S, Maie O: Localized cutaneous cryptococcosis successfully treated with itraconazole: Review of medication in 18 cases reported in Japan. Mycoses 1990;33:455–463.
13.
Feldman SR, Fleischer AB, Resnick SD: Fluconazole treatment of cutaneous cryptococcosis. Arch Dermatol 1992;128:1045–1046.
14.
Gordon PM, Ormerod AD, Harvey G, Atkinson P, Best PV: Cutaneous cryptococcal infection without immunodeficiency. Clin Exp Dermatol 1994;19:181–184.
15.
Antony SA, Antony SJ: Primary cutaneous cryptococcosis in nonimmunocompromised patients. Cutis 1995;56:96–98.
16.
Naka W, Masuda M, Konohama A, Konohana A, Shinoda T, Nishikawa T: Primary cutaneous cryptococcosis and Cryptococcus neoformans serotype D. Clin Exp Dermatol 1995;20:221–225.
17.
Micalizzi C, Persii A, Parodi A: Primary cutaneous cryptococcosis in an immunocompetent pigeon keeper. Clin Exp Dermatol 1997;22:195–197.
18.
Hamann ID, Gillespie RJ, Ferguson JK: Primary cryptococcal cellulitis caused by Cryptococcus neoformans var. gattii in an immunocompetent host. Australas J Dermatol 1997;38:29–52.
19.
Sánchez-Albisua B, Rodriguez-Peralto JL, Romero G, Alonso J, Vanaclocha F, Iglesias L: Cryptococcal cellulitis in an immunocompetent host. J Am Acad Dermatol 1997;36:109–112.
20.
Patel P, Ramanathan J, Kayser M, Baran J: Primary cutaneous cryptococcosis of the nose in an immunocompetent woman. J Am Acad Dermatol 2000;43:344–346.
21.
Mitchell DH, Sorrell TC, Allworth AM, Heath CM, McGregor AR, Papanaoum K, Richards MJ, Gottlieb T: Cryptococcal disease of the CNS in immunocompetent hosts: Influence of cryptococcal variety on clinical manifestations and outcome. Clin Infect Dis 1995;20:611–616.
22.
Schupbach CW, Wheeler CE, Briggaman RA: Cutaneous manifestations of disseminated cryptococcosis. Arch Dermatol 1976;112:1734–1740.
23.
Massa MC, Doyle JA: Cutaneous cryptococcosis simulating pyoderma gangrenosum. J Am Acad Dermatol 1981;5:32–36.
24.
Manrique P, Mayo J, Alvarez JA, Ganchegui T, Zabalza I, Flores M: Polymorphous cutaneous cryptococcosis: Nodular, herpes-like and molluscum-like lesions in a patient with the acquired immunodeficiency syndrome. J Am Acad Dermatol 1992;26:122–124.
25.
Ochoa Gómez L, Lisa Catón V, del Cura Ortiz E, Martes Cativiella P, Campo Hernández JM: Criptococosis cutánea como forma de inicio de criptococosis diseminada. Actas Dermosifiliogr 1990;81:561–562.
26.
Izu Belloso R, Careaga Alzaga JM, López Fernández I, Pintos Neyra JM, Uruñuela Bernedo J: Criptococosis cutánea primaria en un paciente VIH+. Actas Dermosifiliogr 1999;90:616–620.
27.
Noble RC, Fajardo LF: Primary cutaneous cryptococcosis: Review and morphologic study. Am J Clin Pathol 1972;57:13–22.
28.
Handa S, Chakraborty A, Kumar B: Primary cutaneous cryptococcosis in an immune competent patient. J Eur Acad Dermatol Venereol 1998;10:167–169.
29.
Bellosta M, Gaviglio MR, Mosconi M, Cavanna C, Viglio A, Rabbiosi G: Primary cutaneous cryptococcosis in an HIV-negative patient. Eur J Dermatol 1999;9:224–226.
30.
Anonymous: Cryptococcosis and AIDS (editorial). Lancet 1988;i:1434–1436.
31.
Denning DW, Tucker RM, Hanson LH, Stevens DA: Itraconazole in opportunistic mycoses: Cryptococcosis and aspergillosis. J Am Acad Dermatol 1990;23:602–607.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.